Viking Therapeutics completes enrollment in Phase 2 trial of VK2735
Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...
Physician's Weekly5d
GLP-1 Receptor Agonists and Hematologic Cancer Risk in Type 2 Diabetes
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
European Medical Journal11d
GLP-1 Agonists May Lower Haematologic Cancer Risk in Type 2 Diabetes
A recent study suggests that GLP-1 receptor agonists (GLP-1RAs) may lower the risk of hematologic cancers, including leukemia ...
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.